Completed PHASE4 INTERVENTIONAL 3-arm NCT01295151

SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (SWITCH)

Randomised-controlled Trial of Switching to Alternative Tumour-necrosis Factor (TNF)-Blocking Drugs or Abatacept or Rituximab in Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug

Sponsor: Julia Brown

Conditions Rheumatoid Arthritis

Interventions Abatacept Adalimumab Certolizumab Pegol Etanercept Golimumab Infliximab Rituximab

Updated 5 times since 2017 Last updated: Nov 1, 2016 Started: Aug 31, 2011 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Rheumatoid Arthritis and is currently completed. Julia Brown leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Julia Brown

Data source: University of Leeds

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom